Adial Pharmaceuticals Announces Exclusive Collaboration Framework with Molteni Farmaceutici for European Commercialization of AD04

Potential Deal Could Yield Nearly \$60 Million in Royalties and Milestones

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company specializing in treatments for addiction and related disorders, announced on March 3, 2026, that it has entered into a significant collaboration framework agreement with Molteni Farmaceutici, a specialty pharmaceutical company based in Florence, Italy. This exclusive framework sets the stage for the commercialization of Adial’s lead product, AD04, across Europe.

Key Points of the Collaboration

• Exclusive European Partnership: Molteni has been granted exclusive rights to evaluate and plan the commercialization of AD04 across Europe. This includes a period of exclusivity for due diligence, assessment, and launch planning.
• Financial Terms: The planned definitive agreement is expected to include:
  • An upfront payment to Adial upon execution
  • Milestone payments tied to clinical development and commercial progress
  • Tiered royalties on European net sales of AD04, ranging from high single digits to low double digits

  The total potential value from these royalties and milestones is estimated at nearly \$60 million, assuming successful clinical progress and market introduction.

• Strategic Importance: This marks Adial’s first commercial partnership and establishes a clear European pathway for AD04 as it advances toward pivotal Phase 3 development.

Operational and Strategic Developments

• Molteni’s Credentials: Established in 1892, Molteni is a leader in pain management and Substance Use Disorder (SUD) treatments, with robust in-house capabilities for manufacturing, R&D, regulatory compliance, supply chain, and commercial operations. Their strong European and global distribution network further supports the partnership.
• Recent Advancements by Adial:
  • Precision Medicine Approach: Adial has reanalyzed clinical data to identify a specific single nucleotide polymorphism (SNP) that drives efficacy. By focusing on patients with the responsive genotype, Adial anticipates a more targeted, cost-effective, and de-risked Phase 3 clinical program with higher chances of success.
  • Integrated Regulatory Strategy: The company has aligned its clinical endpoints to satisfy both US and European regulators, supporting simultaneous development for the US, EU, and UK markets.
  • Manufacturing Readiness: Supply chain agreements have been secured with leading manufacturers such as Thermo Fisher Scientific and Cambrex, ensuring reliable production for clinical and commercial use.
  • Intellectual Property: A new patent application covering the latest clinical findings could extend AD04’s commercial exclusivity (Loss of Exclusivity, LOE) from 2031 to 2045—potentially adding over a decade of market protection.
  • Genetic Screening Simplification: The company has transitioned from a blood draw to a quick and cost-effective cheek swab test for genotype screening, enhancing physician and patient adoption.

Executive Commentary

Cary Claiborne, President and CEO of Adial, emphasized that this framework is a “significant milestone” for Adial, highlighting Molteni’s expertise in SUD and its integrated European operations as key strengths for the partnership. Gianluca Corbinelli, CEO of Molteni, echoed this sentiment, noting the large unmet need in SUD treatment and Molteni’s readiness to commercialize a genetically targeted therapeutic like AD04.

Potential Impact for Shareholders

• First Commercial Partnership: This is Adial’s inaugural commercial agreement, validating the commercial potential of AD04 and opening the door for significant non-dilutive financial inflows.
• Near-Term Catalysts: The framework is subject to a definitive agreement, which if executed, will trigger upfront and future milestone payments. Execution of this deal and subsequent clinical progress are likely to be material share price drivers.
• Regulatory and Clinical Progress: Adial is actively pursuing commercial partnerships in the US and intends to begin its pivotal Phase 3 program soon. Success in these areas could have a substantial impact on the company’s valuation.
• Patent Extension: The possibility of extending market exclusivity to 2045 provides a major competitive advantage and enhances the long-term revenue potential of AD04.

Forward-Looking Statements and Risks

The company cautions that the collaboration framework is non-binding and subject to the execution of a final definitive agreement. Risks include the possibility of not reaching a final agreement, clinical or regulatory setbacks, challenges in securing necessary funding, and risks related to market acceptance and patent validity. Investors should read these risks alongside the company’s most recent SEC filings.

Contact Information

Investor Relations:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should consult company filings and their own advisors before making investment decisions.

View ADIAL PHARMACEUTICALS, INC. Historical chart here